Investing.com - Cellectis reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Cellectis announced earnings per share of $-0.24 on revenue of $7.76M. Analysts polled by Investing.com anticipated EPS of $-0.8234 on revenue of $11.14M.
Cellectis shares are down 7.21% from the beginning of the year and are trading at $12.23 , down-from-52-week-high.They are under-performing the Nasdaq 100 which is up 26.83% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by J&J on Tuesday, October 19, 2021, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Novo Nordisk ADR had beat expectations on Wednesday with third quarter EPS of $0.8209 on revenue of $5.55B, compared to forecast for EPS of $0.7768 on revenue of $5.4B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar